Supernus Pharmaceuticals (SUPN) Expected to Post Earnings of $0.46 Per Share

Wall Street brokerages forecast that Supernus Pharmaceuticals (NASDAQ:SUPN) will announce earnings of $0.46 per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Supernus Pharmaceuticals’ earnings. The lowest EPS estimate is $0.42 and the highest is $0.50. Supernus Pharmaceuticals reported earnings per share of $0.32 in the same quarter last year, which would suggest a positive year over year growth rate of 43.8%. The business is expected to issue its next earnings report on Wednesday, August 1st.

On average, analysts expect that Supernus Pharmaceuticals will report full-year earnings of $1.91 per share for the current fiscal year, with EPS estimates ranging from $1.85 to $2.00. For the next year, analysts expect that the company will post earnings of $2.65 per share, with EPS estimates ranging from $2.22 to $3.05. Zacks’ EPS averages are a mean average based on a survey of analysts that cover Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.26 by $0.18. The business had revenue of $88.44 million during the quarter, compared to the consensus estimate of $87.84 million. Supernus Pharmaceuticals had a net margin of 21.89% and a return on equity of 30.18%.

SUPN has been the subject of several research analyst reports. BidaskClub downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, January 26th. Berenberg Bank initiated coverage on shares of Supernus Pharmaceuticals in a report on Thursday, February 1st. They set a “buy” rating and a $66.00 target price for the company. ValuEngine raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Finally, Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Saturday, May 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $51.36.

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 67,132 shares of the business’s stock in a transaction dated Friday, May 11th. The shares were sold at an average price of $53.11, for a total value of $3,565,380.52. Following the completion of the sale, the vice president now owns 32,500 shares of the company’s stock, valued at approximately $1,726,075. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Padmanabh P. Bhatt sold 7,868 shares of the business’s stock in a transaction dated Tuesday, May 15th. The shares were sold at an average price of $57.93, for a total transaction of $455,793.24. Following the completion of the sale, the vice president now directly owns 7,868 shares of the company’s stock, valued at approximately $455,793.24. The disclosure for this sale can be found here. Insiders sold a total of 152,850 shares of company stock valued at $7,596,524 in the last three months. Insiders own 6.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of SUPN. Public Employees Retirement Association of Colorado bought a new stake in Supernus Pharmaceuticals in the 4th quarter valued at about $188,000. Elkfork Partners LLC bought a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $217,000. Sigma Planning Corp bought a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $219,000. Wesbanco Bank Inc. bought a new stake in shares of Supernus Pharmaceuticals during the 1st quarter worth approximately $229,000. Finally, Parametrica Management Ltd bought a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $247,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

Shares of SUPN stock traded up $0.40 during midday trading on Friday, hitting $54.95. 37,149 shares of the company were exchanged, compared to its average volume of 908,313. The company has a market capitalization of $2.85 billion, a price-to-earnings ratio of 43.61 and a beta of 1.14. The company has a debt-to-equity ratio of 0.90, a quick ratio of 4.74 and a current ratio of 4.90. Supernus Pharmaceuticals has a 52 week low of $33.30 and a 52 week high of $59.05.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply